| Previous Close | 0.0469 |
| Open | 0.0474 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0469 - 0.0469 |
| 52 Week Range | 0.0403 - 0.1845 |
| Volume | 532,354 |
| Avg. Volume | 687,848 |
| Market Cap | 11.483M |
| Beta (3Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0920 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.34 |
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB:INNVD) today announced preliminary annual 2018 net revenue is estimated to be $24.0 million or approximately 2.7x the annual 2017 net revenue of $8.8 million. Innovus Pharma’s annual 2018 anticipated net revenue results are preliminary and based on the most current information available and are subject to completion of the audited consolidated financial statements for the year ended December 31, 2018, which are to be filed with the Securities and Exchange Commission (“SEC”) as part of the Company’s Annual Report on Form 10-K (“Annual Report”) no later than April 1, 2019. Actual results may differ from the preliminary results reported herein.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it launched in Canada its product Diabasens® as a Natural Health Product (“NHP”), for the indication to relieve cutaneous pain associated with diabetic neuropathy. The product is available as an over-the-counter (“OTC”) or behind the counter product and does not require a prescription.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that received approval from Health Canada to market its product RecalMax™ as a Natural Health Product (“NHP”), for the indications to temporarily relieve symptoms of mental fatigue and sensation of weakness and support cognitive functions including mental focus and stamina. The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it received approval from Health Canada to market its product Diabasens® as a Natural Health Product (“NHP”), for the indication to relieve cutaneous pain associated with diabetic neuropathy. The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.
BH™ Testosterone Booster Capsules, is the Tenth Innovus Pharma Product Approved in Canada to Date
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that its subsidiary, Novalere, Inc., has launched its product line into the hemp-derived, cannabinoid (“CBD”) oil-based products with the introduction of MZS Sleeping Aid™, a dietary supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either a 100 or 250 mg of hemp-derived CBD oil.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the submission of regulatory filings by its international distribution partner, Lavasta Pharma FZ-LLC, a company based in Dubai (“Lavasta”) for the commercialization of ProstaGorx® in the United Arab Emirates and Kuwait. Lavasta also has rights to this product in the Kingdom of Saudi Arabia, Algeria, Egypt, Lebanon, Jordan, Morocco, Tunisia, Bahrain, Oman, Qatar and Turkey, among other countries and is currently expected to continue to file for approval in the rest of its territory during this year.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that its FlutiCare® OTC product for the relief of seasonal allergies is currently ranked #2 behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray categories. In addition, FlutiCare® is currently ranked #6 in Amazon’s Best Moisturizing Nasal Sprays category, #11 in the Best Allergy Medicine category and #41 in the Sinus Medicine category.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its Xyralid® Suppositories, for the reduction of swelling or inflammation of hemorrhoidal tissues and provides pain relief from burning, itching and discomfort. Xyralid® Suppositories received a Product License Application (“PLA”) in Canada and the product is available as an over-the-counter (“OTC”) or behind the counter drug and will not require a prescription.
Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has entered into a definitive agreement with a healthcare-dedicated institutional investor for the sale of 45,306,347 shares of common ...
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the acquisition for cash of all of the assets of SupplementHunt.com, an E-Commerce storefront with proprietary sales platform and marketing technology.
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the enrollment of the first participant in the clinical study to evaluate the effect and tolerance of Musclin™ dietary supplement. The study is being conducted at a single site in the United States and is expected to enroll up to 20 healthy subjects.
NEW YORK, NY / ACCESSWIRE / November 28, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Innovus Pharmaceuticals, Inc. (INNV) with a Target Price of $0.80. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing, and development of over-the-counter (OTC) medicine and consumer care products to improve men's and women's health, respiratory disease and vitality. Led by CEO Dr. Bassam Damaj, Innovus is based in San Diego, CA and has demonstrated robust growth in its product offerings and annual revenues since we initiated coverage on the company in September 2014.
There was a lot of good news in Innovus’ (INNV) third quarter report – higher subscription sales, strong growth in Canada and a slight decrease in absolute marketing spend. • Management’s comments were more focused than on the previous call and emphasized steps the INNV is taking to move to positive operating cash flow and, ultimately GAAP profitability. • Much of INNV’s path to profitability relies on increasing its subscription persistency.
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men’s and women's health and respiratory diseases, announced today that the Company has acquired four branded topical products from Boston Topicals, LLC (“Boston Topicals”), expanding its retail and e-commerce presence in the Company’s current highest revenue grossing category.
The Company is in its Fifth Consecutive Quarter of Net Revenue Growth and Working Diligently Towards Exiting the Fourth Quarter 2018 Profitable
Innovus Pharmaceuticals, Inc., , today announced that the Company will release its September 30, 2018 third quarter financial results on Wednesday, November 14, 2018, after the close of the U.S.
Innovus Pharamceutical (INNV) announced preliminary 3Q18 revenues of $7.0 - $7.1 million, up over 200% from $2.2 million in the year earlier period, but down sequentially from $7.3 million posted in 2Q18. In our initiation report (October 2, 2018), we noted that the supplements business differs from traditional pharmaceutical business. The supplements market relies more on customer interest than disease incidence.
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (INNV), today announced preliminary third quarter 2018 net revenue is estimated to be between $7.0 million to $7.1 million or an approximate 215-219% increase from the third quarter of 2017. Innovus Pharma's third quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated financial statements for the third quarter of 2018, which are to be filed with the SEC no later than November 14, 2018. “We are excited that the exceptional growth in our sales channels, additional markets and product pipeline which we saw in Q2 2018 is continuing on a fairly even path in Q3 2018 with our estimated third quarter net revenue of between $7.0 million to $7.1 million.
NEW YORK, NY / ACCESSWIRE / October 25, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Innovus Pharmaceuticals, Inc. (INNV) with a Target Price of $0.80. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is a fast-growing commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, announced today that its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip products have become eligible for Medicare reimbursement. Specifically, the two products have been approved as Healthcare Common Procedure Coding System (“HCPCS”) numbers E0607 and A4253 products respectively after review by the Pricing, Data Analysis, and Coding Contractor (“PDAC”) for the U.S. Centers for Medicare and Medicaid Services (“CMS”).
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it plans to expand its product line into the hemp-derived CBD (“Cannabinoid”) oil-based products market beginning in the fourth quarter 2018 with the introduction of MZS Sleeping Aid™, a supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either 100 or 250 mg of hemp-derived CBD oil. Innovus is also interested in expanding into other products using hemp-derived CBD oil that can benefit its customers in both countries and in other markets throughout the world.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval from Amazon® for the expansion of its Amazon® stores to Japan. The additional store will increase the Company’s worldwide Amazon® store presence to its first country in Asia and is in addition to the Company’s Amazon® stores in the United States, Canada, Mexico and its new stores opening in the United Kingdom, France, Germany, Spain and Italy which it expects to launch in Q1 2019 or before.
Innovus Pharmaceutical (INNV) commercializes and markets OTC and consumer health products. In the past year, the Company has introduced seven new products. Innovus has a strong pipeline and a very active direct marketing effort.